Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

By H. Meijers-Heijboer, B. V. van Geel, W. van Putten, S. Henzen‐Logmans, C. Seynaeve, M. Menke-Pluymers, C. Bartels, L. Verhoog, A. V. D. van den Ouweland, M. Niermeijer and 2 more. New England Journal of Medicine, 2001

962 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/d925043470d1302d56aadb2b9a95178e5b7126c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Barbara L. Weber
2. Timothy R. Rebbeck
3. M. King

In Public Health, Environmental and Occupational Health

1. Barbara L. Weber
2. Patricia A. Ganz

Citations in the corpus

• Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. (2004, neutral): “Posthysterectomy 3 (1) 48 (5) 24 (5) 75 (4)”
• Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, positive): “Risk-reducing mastectomy is a highly effective strategy for breast cancer risk reduction.(20,21) In our prospec-”
• Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. (2005, background): “BRCA2 mutations compared with so-called watchful waiting.(13-16) Nonetheless, the perceived mutilating effects of mastectomy make the decision for surgical prevention difficult, and current national guidelines do not recommend it as standard management.”
• Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. (2006, background): “Clinical options for women at high genetic risk of breast cancer include screening starting at a young age,(19) the use of highly sensitive detection methods,(20) and prophylactic surgeries of the ovaries or breast.(21-27) Because prophylactic surgeries, while highly effective in reducing risk, are ”
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. (2001, background): “Over 3 years of follow-up, invasive breast cancer occurred in 8 of 63 women with inherited BRCA1 or BRCA2 mutations, who had opted for surveillance alone, but in none of 76 women who underwent prophylactic mastectomy.(37) Other data indicates that early prophylactic oophorectomy reduces the risk of ”
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2004, background): “In the only other study of BRCA1/2 mutation carriers to date, Meijers-Heijboer et al [6] reported no postbilateral prophylactic mastectomy breast cancers in 76 BRCA1/2 mutation carriers after 2.”